Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma

Osteosarcoma Clinical Trial

Official title:

Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osterosarcoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03358628
• Other study ID #: 2017PHB278-01
• Status: Not yet recruiting
• Phase: N/A
• First received: November 25, 2017
• Last updated: November 29, 2017
• Start date: February 1, 2018
• Est. completion date: January 31, 2025

Study information

• Verified date: November 2017
• Source: Peking University People's Hospital
• Contact: Tingting Ren, PhD
• Phone: 86-10-88324470
• Email: tumorcenter[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

By obtaining clinical specimens from participants with high-grade bone and soft tissue sarcomas to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with individualized cancer treatment options

Description:

Patient-derived xenografts (PDX) are increasingly used as tools for drug development in pre-clinical settings, and have been shown to recapitulate the histology and behavior of the cancers from which they are derived. Although, they have been commonly used productively as pre-clinical disease models to study disease biology and drug response, they have not been used prospectively to inform clinical management. PDX have been employed to inform clinical decision-making in small studies, which have shown high concordance between individual PDX and patient responses to therapy. While encouraging, the role of this approach in bone and soft tissue sarcomas and in the context of genomic drug matching strategies remains undefined. This has created an opportunity to evaluate the utility of PDX as clinical predictors to direct the use of chemo- and targeted therapies in combination with comprehensive genomic and epigenetic analysis for patients with bone and soft tissue sarcomas.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: January 31, 2025
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age >18 years;

2. Diagnosis confirmed histologically and reviewed centrally;

3. Prior treatment (completed >4 weeks before trial entry) consisted of standard high-grade osteosarcoma chemotherapy agents including doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide; metastatic relapsed and unresectable progressive disease (PD);

4. Eastern Cooperative Oncology Group performance status 0-1 with a life expectancy >3 months;

5. Adequate renal, hepatic, and hemopoietic function;

6. Normal or controlled blood pressure;

7. Surgery and/or radiotherapy completion at least 1 month before enrollment.

Exclusion Criteria:

1. Central nervous system metastasis;

2. Have had other kinds of malignant tumors at the same time;

3. Cardiac insufficiency or arrhythmia;

4. Uncontrolled complications, such as diabetes mellitus and so on;

5. Coagulation disorders;

6. Urine protein= ++;

7. Pleural or peritoneal effusion that needs to be handled by surgical treatment;

8. Combined with other infections or wounds.

Related Conditions & MeSH terms

• Osteosarcoma

Intervention

Other:
• Molecular Profiling & In Vivo drug testing in PDX
Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University People's Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure of drug sensitive PDX to a panel of drugs as a predictor of clinical response in matched host	Sensitivity measured by tumor growth inhibition (>80%) or objective tumor response (regression) as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria.	up to 2 years